NF2, CPTAC-1739 - CPTAC Assay Portal (original) (raw)
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.
NF2
Protein Sequence hover to view complete sequence
| 10 | 20 | 30 | 40 | 50 |
|---|---|---|---|---|
| MAGAIASRMS | FSSLKRKQPK | TFTVRIVTMD | AEMEFNCEMK | WKGKDLFDLV |
| 60 | 70 | 80 | 90 | 100 |
| CRTLGLRETW | FFGLQYTIKD | TVAWLKMDKK | VLDHDVSKEE | PVTFHFLAKF |
| 110 | 120 | 130 | 140 | 150 |
| YPENAEEELV | QEITQHLFFL | QVKKQILDEK | IYCPPEASVL | LASYAVQAKY |
| 160 | 170 | 180 | 190 | 200 |
| GDYDPSVHKR | GFLAQEELLP | KRVINLYQMT | PEMWEERITA | WYAEHRGRAR |
| 210 | 220 | 230 | 240 | 250 |
| DEAEMEYLKI | AQDLEMYGVN | YFAIRNKKGT | ELLLGVDALG | LHIYDPENRL |
| 260 | 270 | 280 | 290 | 300 |
| TPKISFPWNE | IRNISYSDKE | FTIKPLDKKI | DVFKFNSSKL | RVNKLILQLC |
| 310 | 320 | 330 | 340 | 350 |
| IGNHDLFMRR | RKADSLEVQQ | MKAQAREEKA | RKQMERQRLA | REKQMREEAE |
| 360 | 370 | 380 | 390 | 400 |
| RTRDELERRL | LQMKEEATMA | NEALMRSEET | ADLLAEKAQI | TEEEAKLLAQ |
| 410 | 420 | 430 | 440 | 450 |
| KAAEAEQEMQ | RIKATAIRTE | EEKRLMEQKV | LEAEVLALKM | AEESERRAKE |
| 460 | 470 | 480 | 490 | 500 |
| ADQLKQDLQE | AREAERRAKQ | KLLEIATKPT | YPPMNPIPAP | LPPDIPSFNL |
| 510 | 520 | 530 | 540 | 550 |
| IGDSLSFDFK | DTDMKRLSME | IEKEKVEYME | KSKHLQEQLN | ELKTEIEALK |
| 560 | 570 | 580 | 590 | 595 |
| LKERETALDI | LHNENSDRGG | SSKHNTIKKL | TLQSAKSRVA | FFEEL |
Data source: UniProt
Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs
Uniprot Database Entry PhosphoSitePlus ®
Click a point on a node
to view detailed assay information below
All other points link out to UniProt
Phosphorylation Acetylation Ubiquitylation Other
loading
Assay Details for CPTAC-1739 Collapse assay details
Data source: Panorama
Official Gene Symbol
NF2
Peptide Modified Sequence
LT[+80.0]LQSAK
Modification Type
Phospho (ST)
Protein - Site of Modification
581
Peptide - Site of Modification
2
Peptide Start
580
Peptide End
586
CPTAC ID
CPTAC-1739
Peptide Molecular Mass
839.4154
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM or SRM
Enrichment Method
Titanium Dioxide
Matrix
Ovarian cancer cell lysate
Submitting Laboratory
Pacific Northwest National Laboratory
Submitting Lab PI
Tao Liu
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
TSQ Vantage
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Waters nanoACQUITY (Part Number 176016000)
Column Packing
Waters BEH C18, 1.7 um 130 Å (Part Number 186007485)
Column Dimensions
100 um x 100 mm
Flow Rate
0.5 uL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-TiO2SRM
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV
| n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y4 (1+) | 15.4 | 7 | 12.6 | 13.7 | 9 | 13.5 | 20.6 | 11.4 | 18.5 | 15 | 15 | 15 |
| y5 (1+) | 4.1 | 5.5 | 6.2 | 7.6 | 6.9 | 7.7 | 8.6 | 8.8 | 9.9 | 15 | 15 | 15 |
| y6 (1+) | 25.3 | 7.7 | 11.7 | 36.6 | 10.9 | 14.7 | 44.5 | 13.3 | 18.8 | 15 | 15 | 15 |
| sum | 5.9 | 3 | 6.2 | 8.1 | 3.5 | 6.6 | 10 | 4.6 | 9.1 | 15 | 15 | 15 |